# Digital intervention mylovia improves sexual functioning in women with sexual dysfunction in randomized controlled trial

**Authors:** Wiebke Blaszcyk, Melanie Büttner, Linda T. Betz, Antje Riepenhausen, Gitta A. Jacob, Jan Philipp Klein, Johanna Schröder

PMC · DOI: 10.1038/s41746-026-02385-z · NPJ Digital Medicine · 2026-02-03

## TL;DR

A digital therapy called mylovia improved sexual functioning in women with sexual dysfunction, showing lasting benefits over three to six months.

## Contribution

Mylovia is a novel digital intervention based on CBT and mindfulness that shows efficacy in treating female sexual dysfunction.

## Key findings

- The intervention group showed significantly greater improvements in sexual functioning compared to the control group.
- Improvements were maintained at six months and included sexual desire, satisfaction, and pain-related behaviors.
- The intervention had no significant adverse effects and was as effective as existing psychosocial treatments.

## Abstract

Given the widespread issue of female sexual dysfunction and the scarcity of treatment options, novel therapeutic approaches are needed. This randomized controlled trial evaluated the use of mylovia©, a self-guided digital intervention for female sexual dysfunction and sexual pain disorder based on CBT and mindfulness, in addition to treatment as usual (TAU) compared to TAU plus information material. 252 women participated. At three months, the intervention group showed significantly greater improvements (Cohen’s d = 0.51, p < 0.001) in sexual functioning, measured by the Female Sexual Function Index (FSFI), with effects maintained at six months. Clinical relevance was confirmed by Reliable Change Index (RCI) responder analysis. The intervention group also reported greater improvements in sexual desire, satisfaction, and pain-related cognitions and behaviors. There were no significant between-group differences in depressive symptoms or adverse events. The intervention demonstrated comparable efficacy to existing psychosocial treatments, offering a digital therapeutic that could narrow the current gender healthcare gap. This trial was registered on ClinicalTrials.gov on 24 January 2024, with the identifying number NCT06237166.

## Linked entities

- **Diseases:** sexual dysfunction (MONDO:0002134)

## Full-text entities

- **Diseases:** multiple sclerosis (MESH:D009103), pain disorder (MESH:D013001), Sexual pain (MESH:D010146), sexual dsyfunction (MESH:D050035), hypoactive sexual desire (MESH:D020018), borderline personality disorder (MESH:D001883), Depressive Symptoms (MESH:D003866), trauma (MESH:D014947), bipolar disorder (MESH:D001714), cancer (MESH:D009369), Sexual Dysfunctions (MESH:D012735), major depressive disorder (MESH:D003865), substance use disorder (MESH:D019966), TAU (MESH:D054990), schizophrenia (MESH:D012559), Impairments in sexual functioning (MESH:D012734), psychiatric (MESH:D001523), sexual abuse (MESH:D000082002)
- **Chemicals:** MBT (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12868880/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12868880/full.md

## References

9 references — full list in the complete paper: https://tomesphere.com/paper/PMC12868880/full.md

---
Source: https://tomesphere.com/paper/PMC12868880